knowledge -WSS

knowledge

author：leisure time 2025-09-27 09:44:43 - browse：553

A sign of Elevance Health behind some flowers — coverage from STAT — Michael Conroy/AP

Paul Marchetti, the head of insurer Elevance Health’s pharmacy benefit manager, has left the company amid a wave of consumer complaints about patients receiving incorrect medicines or being unable to get their prescriptions filled.

Elevance did not confirm Marchetti’s departure as the president of CarelonRx, but according to his Linkedin profile, he left the company in May.

Elevance, the second-largest commercial health insurer in the country by market share, uses its CarelonRx subsidiary to manage its pharmacy business. In online complaints, CarelonRx customers point toward January 1 as the date when issues with obtaining their prescriptions from the company began. The reported problems include safety issues like receiving other people’s medications or receiving medications they discontinued years ago.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Why Congress must ban federal programs from using QALYs

WSS

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

WHO recommends dropping component of many flu vaccines

Tocagen's brain cancer gene therapy trial continues. Investors worry

Why Congress must ban federal programs from using QALYs

Would Medicare drug price negotiations stall in a shutdown?

Tocagen's brain cancer gene therapy trial continues. Investors worry

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

I learned firsthand about improving diversity in clinical trials

After affirmative action ruling, medical educators look to 'holistic review'

WHO recommends dropping component of many flu vaccines

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Apple is now the first public company to be valued at $3 trillion

Study identifies new proteins linked to dementia risk 25 years later

The cancer drug shortage isn’t new — and neither are the solutions

Address the ethical violations that led to 'Three Identical Strangers'

focus

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Listen: Who gets the credit for GLP

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Address the ethical violations that led to 'Three Identical Strangers'

Paxlovid should be available without a positive Covid test

Wikipedia

hotspot

knowledge

knowledge